Aoxing Pharmaceutical Company, Inc. Regains Full Compliance with NYSE MKT Listing Standards

JERSEY CITY, NJ / ACCESSWIRE / April 27, 2015 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) (“Aoxing Pharma” or the “Company”), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic, pain-management and addiction treatment pharmaceuticals, today announced that the Company has received notification from the NYSE MKT that the Company is now back in compliance with the NYSE MKT’s continued listing standards as a result of meeting the required level of shareholders’ equity.

During 2013 and subsequently, NYSE MKT informed Aoxing Pharma that it was out of compliance with several of the continued listing requirements specified in the NYSE MKT Company Guide. As of April 24, 2015, Aoxing Pharma meets all requirements for continued listing on the NYSE MKT.

The Company expects to release its Third Quarter 2015 results on or about May 15, 2015.

About Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing Pharma has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the SFDA. For more information, please visit: www.aoxingpharma.com.

CONTACT:

Aoxing Pharmaceutical Company
646-367-1747
investor.relations@aoxingpharma.com

SOURCE: Aoxing Pharmaceutical Company, Inc.

ReleaseID: 428218